Year
2023
-
US FDA advisers to weigh full approval for Eisai-Biogen’s Alzheimer’s drug
-
Potential Nitrosamine Contamination Results in Another Voluntary Pharmaceutical Recall
-
Sumitomo Pharma’s Ewing Sarcoma Candidate Gains Orphan Drug Status
-
Biogen to develop amyloid beta-targeting antibody platform
-
Regenxbio Gene Therapy Candidate Gets Fast Track Status for Duchenne Muscular Dystrophy
-
FDA rejects Eli Lilly’s mirikizumab for ulcerative colitis, citing manufacturing concerns
-
FDA grants breakthrough device status for Genetesis’ CardioFlux MCG
-
FDA Updates Safety Labeling and Prescribing Information for Opioid Pain Meds
-
Pipeline Therapeutics Announces Global License and Development Agreement for Investigational Neuroscience Therapy, PIPE-307
-
Omega-3 fatty acids might reduce cognitive decline risk